BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18793847)

  • 1. Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
    Fucini RV; Hanan EJ; Romanowski MJ; Elling RA; Lew W; Barr KJ; Zhu J; Yoburn JC; Liu Y; Fahr BT; Fan J; Lu Y; Pham P; Choong IC; VanderPorten EC; Bui M; Purkey HE; Evanchik MJ; Yang W
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5648-52. PubMed ID: 18793847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors.
    Hanan EJ; Fucini RV; Romanowski MJ; Elling RA; Lew W; Purkey HE; VanderPorten EC; Yang W
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5186-9. PubMed ID: 18790636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.
    Emmitte KA; Adjabeng GM; Andrews CW; Alberti JG; Bambal R; Chamberlain SD; Davis-Ward RG; Dickson HD; Hassler DF; Hornberger KR; Jackson JR; Kuntz KW; Lansing TJ; Mook RA; Nailor KE; Pobanz MA; Smith SC; Sung CM; Cheung M
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1694-7. PubMed ID: 19237286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of thiophene inhibitors of polo-like kinase.
    Emmitte KA; Andrews CW; Badiang JG; Davis-Ward RG; Dickson HD; Drewry DH; Emerson HK; Epperly AH; Hassler DF; Knick VB; Kuntz KW; Lansing TJ; Linn JA; Mook RA; Nailor KE; Salovich JM; Spehar GM; Cheung M
    Bioorg Med Chem Lett; 2009 Feb; 19(3):1018-21. PubMed ID: 19097784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity-determining residues in Plk1.
    Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
    Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.
    Elling RA; Fucini RV; Romanowski MJ
    Acta Crystallogr D Biol Crystallogr; 2008 Sep; 64(Pt 9):909-18. PubMed ID: 18703838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
    Schneider G; Geppert T; Hartenfeller M; Reisen F; Klenner A; Reutlinger M; Hähnke V; Hiss JA; Zettl H; Keppner S; Spänkuch B; Schneider P
    Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Johnson EF; Stewart KD; Woods KW; Giranda VL; Luo Y
    Biochemistry; 2007 Aug; 46(33):9551-63. PubMed ID: 17655330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
    Chen DX; Huang J; Liu M; Xu YG; Jiang C
    Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.
    Keppner S; Proschak E; Schneider G; Spänkuch B
    ChemMedChem; 2009 Nov; 4(11):1806-9. PubMed ID: 19746360
    [No Abstract]   [Full Text] [Related]  

  • 12. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
    Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
    Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
    Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
    Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imidazo[5,1-f][1,2,4]triazin-2-amines as novel inhibitors of polo-like kinase 1.
    Cheung M; Kuntz KW; Pobanz M; Salovich JM; Wilson BJ; Andrews CW; Shewchuk LM; Epperly AH; Hassler DF; Leesnitzer MA; Smith JL; Smith GK; Lansing TJ; Mook RA
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6214-7. PubMed ID: 18929484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
    Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
    Shafer CM; Lindvall M; Bellamacina C; Gesner TG; Yabannavar A; Jia W; Lin S; Walter A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4482-5. PubMed ID: 18672368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the catalytic domain of human polo-like kinase 1.
    Kothe M; Kohls D; Low S; Coli R; Cheng AC; Jacques SL; Johnson TL; Lewis C; Loh C; Nonomiya J; Sheils AL; Verdries KA; Wynn TA; Kuhn C; Ding YH
    Biochemistry; 2007 May; 46(20):5960-71. PubMed ID: 17461553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.
    Beria I; Valsasina B; Brasca MG; Ceccarelli W; Colombo M; Cribioli S; Fachin G; Ferguson RD; Fiorentini F; Gianellini LM; Giorgini ML; Moll JK; Posteri H; Pezzetta D; Roletto F; Sola F; Tesei D; Caruso M
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6489-94. PubMed ID: 20932759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
    Reindl W; Strebhardt K; Berg T
    Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.
    Caruso M; Valsasina B; Ballinari D; Bertrand J; Brasca MG; Caldarelli M; Cappella P; Fiorentini F; Gianellini LM; Scolaro A; Beria I
    Bioorg Med Chem Lett; 2012 Jan; 22(1):96-101. PubMed ID: 22154349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.